Glioblastoma radiosensitization by pimozide
MLK4 activates the NF-κB network to drive mesenchymal transition in glioblastoma
Mesenchymal stromal cells and interferon α (IFNα) in cancer immunotherapy
Rethinking clinical trial design: maximizing the results from each clinical trial participant
INTEGRATE phase II trial: regorafenib vs. placebo in pretreated metastatic gastric cancer patients—is there anything new?
Hedgehog signaling in colorectal cancer: a spiny issue gets smoothened
An ace in the hole for hepatocellular carcinoma: yttrium-90 radioembolization
New insights into the mechanisms of EZH2’s promotion of oncogenesis
Is there still an open window in metastatic castration resistant prostate cancer immunotherapy horizon?
Risk of contralateral breast cancer amongst BRCA1/2 mutation carriers
Determination of the optimal screen interval in low-dose CT lung cancer screening: are we there yet?
Prostaglandin E2 plays a major role in glioma resistance and progression
Information-dense analysis for information-dense understanding
Thriving where others have faltered—a critical appraisal of the role of patient factors versus treatment effect in JCOG0605 trial in relapsed small cell lung cancer
The use of malaria glycosaminoglycan to block cancers—lessons from the human placenta
A genomic analysis of large cell neuroendocrine carcinoma versus small cell lung cancer: which is which?
Pancreatic cancer cell invasion: mesenchymal switch or just hitchhiking?
Subventricular zone microenvironment protects glioblastoma cells from radiotherapy cytotoxicity: role of the chemokine CXCL12
Sleeve lobectomy or pneumonectomy for non-small cell lung cancer? Searching for an optimal balance between oncological, surgical and functional results
The potential role of curcumin in prostate cancer: the importance of optimizing pharmacokinetics in clinical studies
The unexpected high risk of occurrence or recurrence of hepatocellular carcinoma after successful antiviral therapy with interferon-free direct-acting antivirals
Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy
Role of adaptive randomization in developing novel therapies for patients with breast cancer
Resistance mechanisms to PD-1 inhibition in melanoma
Advances in molecular genetics of early-stage urothelial carcinoma
Moving from immune phenotyping of colorectal cancer to mechanistic insights on aspirin use
Is microRNA expression profile in prostate cancer dependent on clinicopathologic stage or cell subtype?
Cisplatin, etoposide, and irinotecan for relapsed small-cell lung cancer
Turning the concept of synthetic lethality on its head
Dealing with complexity: prognostic implications of karyotype and mutations in chronic lymphocytic leukemia
Thoracoscopic surgery for lung cancer without interruption of anti-platelet agents: is it really safe?
Is the ColDx assay a valid prognostic marker for stage II colon cancer?
Eribulin in the soft tissue sarcoma therapeutic landscape: little is good, then more is better
Identifying ADP-ribosylation targets by chemical genetics
Implications of the lymph nodal ratio in resected N1 non-small cell lung cancer
Predicting disease recurrence in stage II colon cancer: expression signatures and other biomarkers
Clinical data and role of ceritinib a second-generation ALK tyrosine kinase inhibitor for the treatment of ALK positive non-small cell lung cancer
Unraveling epigenetic regulation of epithelial mesenchymal transition
Biomarker guided treatment of advanced non-small cell lung cancer: does feasibility translate to improvements in patient care?
G-protein coupled receptor PAR1 is overexpressed in glioma progenitor cells
Xist at the edge: silencing at the nuclear periphery extends to X inactivation
Genetic and epigenetic alterations in urothelial carcinoma
Loss of LARP4B, an early event in the tumorigenesis of brain cancer?
A vicious cycle of metabolic interaction between leukemia stem cells and adipose tissues: implications in cachexia and drug resistance
miRNA profile as a predictor of response to chemoradiation therapy for esophageal squamous cell carcinoma
JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function
Is there a role for epidermal growth factor receptor inhibition in the treatment of advanced esophagogastric tumours?
Molecular cross-talk between the liver and white adipose tissue links excessive noURIshment to hepatocellular carcinoma
Lung cancer screening: screening frequency and lung cancer risk
Adding to the targeted therapy toolbox: BRAF and MEK inhibition in the treatment of BRAF V600E metastatic non-small cell lung cancer
Contemporary management of renal angiomyolipomas
MET-inhibitors meet MET mutations in lung cancer
Combination chemotherapy for relapsed small-cell lung cancer—perspective on mechanisms of chemoresistance
MicroRNAs as novel elements in personalized radiotherapy
Perspective on targeting salt-inducible kinase 2 (SIK2) in ovarian cancer metastasis
Protease-activated receptor 1 (PAR1): a promising target for the treatment of glioblastoma?
Neoadjuvant chemotherapy versus chemoradiation for esophageal cancer: no survival difference does not mean no differences
In vivo cancer metabolism is defined by the nutrient microenvironment
IL2 based immunotherapies: towards a personalized and curative antitumor response
Immunotherapy of pancreatic cancer—weal and woe
The regulation of cancer cell glutamine metabolism
Trans-arterial embolization for hepatocellular carcinoma: doxorubicin is not necessary
Cancer-like mutations in non-cancer tissue: towards a better understanding of multistep carcinogenesis
This supplement was published without any sponsorship or funding.